Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 2
1989 1
1991 1
1994 1
1995 1
1997 1
1998 1
2001 2
2003 1
2006 1
2014 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean friedrich s[Author] (344 results)?
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM. Frost JD, et al. Among authors: frierdich s. Cancer. 1997 Jul 15;80(2):317-33. doi: 10.1002/(sici)1097-0142(19970715)80:2<317::aid-cncr21>3.0.co;2-w. Cancer. 1997. PMID: 9217046 Clinical Trial.
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH. Cairo MS, et al. Among authors: frierdich s. J Pediatr Hematol Oncol. 2001 Jan;23(1):30-8. doi: 10.1097/00043426-200101000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11196267 Clinical Trial.
A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study.
Bauer M, Reaman GH, Hank JA, Cairo MS, Anderson P, Blazar BR, Frierdich S, Sondel PM. Bauer M, et al. Among authors: frierdich s. Cancer. 1995 Jun 15;75(12):2959-65. doi: 10.1002/1097-0142(19950615)75:12<2959::aid-cncr2820751225>3.0.co;2-r. Cancer. 1995. PMID: 7773948 Clinical Trial.
16 results